THE US Food and Drug
Administration has approved
Viibryd tablets (vilazodone
hydrochloride) for the treatment of
major depressive disorder in adults.
Available in 10, 20 and 40mg
tablets, the drug’s most common
side effects include diarrhea,
nausea, vomiting, and insomnia.
MEANWHILE the FDA has also
unveiled its 2011 plan to improve
the most common path to market
for medical devices.
Key actions featured in the plan
include streamlining the “de novo”
review process for certain innovative,
lower-risk medical devices; clarifying
when clinical data should be
submitted in a premarket submission;
and establishing a new Center
Science Council of FDA experts to
ensure timely and consistent
science-based decision making.
See www.fda.gov for details.The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jan 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jan 11
from the fields Pharmaceutical (FTFP) is unveiling an information drive targeting community pharmacy, ahead of the 01 Mar commencement of new retail regulations for the sale and distribution of medically prescribed vaping products in pharmacies.